CME: hyperkalemia, patiromer, RAAS, potassium binder, SZC

Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy

Host: Javed Butler, MD, MPH, MBA

Take Post-Test

If you’ve already completed the activity.

Overview
Heart failure is a global pandemic reported to affect at least 26 million people worldwide. Maximizing the inhibition of the renin-angiotensin-aldosterone system (RAAS) using optimally tolerated doses of inhibitors improves outcomes and reduces both morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF).
This case-based simulation will explore appropriate screening and monitoring strategies for patients with HFrEF as well as how to apply evidence-based approaches for maximizing guideline-recommended RAAS inhibitor therapies while managing potassium levels.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Javed Butler, MD, MPH, MBA
Professor & Chair, Department of Medicine
University of Mississippi Medical Center
Jackson, MS
Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma
Reviewers/Content Planners/Authors:
- Sean T. Barrett has nothing to disclose.
- Ben Caref, PhD, has nothing to disclose.
- Megan Clem has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Stephanie Wenick has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Develop screening and monitoring strategies for hyperkalemia in patients with heart failure.
- Apply evidence-based data and guideline recommendations in treatment planning to lower potassium levels to enable patients to maximize their renin-angiotensin-aldosterone inhibitor therapy.
Target Audience
This activity is designed to meet the educational needs of heart failure specialists, cardiologists, primary care physicians, nephrologists, and all other allied healthcare professionals involved in the diagnosis, treatment, and care of heart failure.
Accreditation and Credit Designation Statements
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider
Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.
Commercial Support
This activity is supported by an independent educational grant from Vifor Pharma.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.